Shire's $5.9 Billion Acquisition of Dyax Helps Eliminate a RivalBy
Dyax investors to get $646 million more if DX-2930 is approved
Target company's DX-2930 may generate $2 billion in sales
Shire Plc, whose $30 billion bid to acquire Baxalta Inc. was rebuffed, is buying biotechnology company Dyax Corp. for at least $5.9 billion in cash to gain a promising treatment for a rare genetic disorder and eliminate a key competitor. Shares of Dyax soared.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.